Novavax Inc
$9.35
$0.12 (+1.30%)
$9.15Day Range$9.41
Key Statistics
Market Cap
$1.54B
Shares Outstanding
164.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 5, 1995
Round Lot
100
Locale
US
Trading Data
Day Open
$9.35
Day High
$9.41
Day Low
$9.15
Volume
2.85M
VWAP
$9.31
Prev Close
$9.23
Transactions
--
Acc. Volume
--
About Novavax Inc
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836749 employees21 FIRSTFIELD RD, GAITHERSBURG, MD240-268-2000IPO Dec 5, 1995US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001000694
- Composite FIGI
- BBG000NVSBL7
- Share Class FIGI
- BBG001SGL8G3
- Ticker Root
- NVAX
- SIC Code
- 2836
About Novavax Inc (NVAX) Stock
Novavax Inc (NVAX) closed the 2026-09-16 session at $9.35, up 1.30% versus the previous close (+0.12). The stock opened at $9.35 and traded between $9.15 and $9.41 during that session. Session trading volume was 2.8M shares. The volume-weighted average price (VWAP) is $9.31.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Novavax Inc has a market capitalization of $1.54 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. NVAX is listed on the XNAS exchange. The company employs approximately 749 people. Novavax Inc is headquartered in GAITHERSBURG, MD. The recorded listing date is 1995-12-05.
On this page you can find market NVAX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.